Phase 3 win and rolling NDA filed for a topical rapamycin with no approved rival; approval in H1 2027 is the single gate

Palvella is a clinical-stage company developing a topical drug for microcystic lymphatic malformations, a rare skin condition, which is not yet approved.

Palvella built its case around QTORIN rapamycin, a proprietary topical mTOR inhibitor for microcystic lymphatic malformations, a rare structural vascular disease of the skin with no approved therapy. The Phase 3 SELVA trial met its primary endpoint with high statistical significance across all pre-specified endpoints, and a rolling NDA is underway, shifting the remaining question from efficacy to regulatory execution. The approval risk centers on whether a single pivotal trial in a small orphan population, without an active comparator arm, satisfies FDA, and a competing topical rapamycin program from Quoin Pharmaceuticals represents a potential first-mover threat in the same indication.